Acadian Asset Management’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
Other funds holding RCUS
GS
SCM
WP
Acadian Asset Management's RCUS Position: Q2 2026 in Review
Acadian Asset Management increased its Arcus Biosciences (RCUS) stake by 178% in Q2 2026, buying an estimated $192K and bringing the position to 12,107 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #1514.
Acadian Asset Management first reported a position in RCUS in Q3 2019 and has held it in 14 quarters since. The position peaked at $458K in Q4 2024. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.
- Acadian Asset Management held 12,107 shares of Arcus Biosciences worth $372K as of Q2 2026.
- Acadian Asset Management bought 7,757 Arcus Biosciences shares in Q2 2026, an estimated $192K.
- Arcus Biosciences made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1514 holding.
- Acadian Asset Management first reported a position in Arcus Biosciences in Q3 2019 and has held it in 14 quarters since.
- Acadian Asset Management's Arcus Biosciences position peaked at $458K in Q4 2024.
- 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.